Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Thalidomide provides new hope for patients with difficult to treat liver cancer

Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma, according to data presented at the International Liver Congress 2011.

2 Apr 2011

Biocept, academic collaborators' posters on CTCs to be presented at AACR meeting

Biocept, Inc. today reported that its scientists and academic collaborators will present four posters at the 102nd Annual Meeting of the American Association for Cancer Research taking place in Orlando, Florida April 2-6, 2011.

1 Apr 2011

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Apr 2011

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has completed enrollment in its ALN-VSP Phase I multi-center, multinational, open label, dose escalation clinical trial.

1 Apr 2011

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

31 Mar 2011

CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel

CEL-SCI Corporation announced today that the State of Israel's Ministry of Health has given approval to begin enrollment of subjects for a Phase III clinical trial of Multikine in Israel.

31 Mar 2011

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC).

31 Mar 2011

DSP, Intercept enter license agreement for OCA

Dainippon Sumitomo Pharma Co, Ltd. and Intercept Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid.

30 Mar 2011

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

30 Mar 2011

Smoking withdrawal after liver transplantation may protect against neoplasia development

Spanish researchers have found that liver transplant recipients who quit smoking have a lower incidence of smoking-related malignancies than patients who keep smoking.

30 Mar 2011

Smoking cessation after liver transplantation reduces incidence of malignancy

Spanish researchers have found that liver transplant recipients who quit smoking have a lower incidence of smoking-related malignancies (SRM) than patients who keep smoking. In fact, SRMs were identified in 13.5% of deceased patients and smoking was associated with a higher risk of malignancy in this study. Full findings are published in the April issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

29 Mar 2011

Nordion presents TheraSphere Phase II trial results against liver metastases at SIR meeting

Nordion Inc., a leading provider of products and services to the global health science market, today shared results from the first multi-site, Phase II clinical trial to evaluate TheraSphere® for treatment of metastatic liver cancer.

29 Mar 2011

AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting

AVEO Pharmaceuticals, Inc. today announced that preclinical data on tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and the company's monoclonal antibody pipeline will be presented during poster sessions at the American Association for Cancer Research 102nd Annual Meeting 2011 being held April 2-6, 2011 in Orlando, Fla.

28 Mar 2011

Scientists receive CFCF-AACR grants for carcinoid, pancreatic neuroendocrine tumor research

The American Association for Cancer Research is pleased to announce the recipients of the 2011 Caring for Carcinoid Foundation-AACR Grants for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research and the 2011 Raymond and Beverly Sackler AACR Fellowships for Ileal Carcinoid Tumor Research.

28 Mar 2011

VARI, Gentel Biosciences receive U.S. Patent for new glycan detection technology

Gentel Biosciences, a leader in proteomics tools, and Van Andel Research Institute, a biomedical research institute, jointly announce today the granting of U.S. Patent 7,838,634 for a new method to profile changes in the glycosylation of proteins captured on the surface of an antibody array slide. Gentel first obtained an exclusive right to commercialize the technology in 2006.

25 Mar 2011

MicroRNAs may play a key role in future medicine

Since their discovery in the 1990s, microRNAs have proven to play a complex role in normal and abnormal functioning of many organ systems. In the April issue of Translational Research, entitled "MicroRNAs: A Potential New Frontier for Medicine," an international group of medical experts explores several themes related to our current understanding of microRNAs and the role they may play in the future of medicine.

24 Mar 2011

FDA approves Nordion's TheraSphere IDE for Phase III trial to treat HCC

Nordion Inc., a leading provider of products and services to the global health science market, today announced that it has received U.S. Food and Drug Administration approval to conduct a Phase III clinical trial for TheraSphere® under an Investigational Device Exemption.

23 Mar 2011

MD Anderson receives $2.7 million NCI grant for acupuncture study in cancer

The University of Texas MD Anderson Cancer Center has been awarded a grant to study whether xerostomia, a debilitating side effect caused by head and neck cancer radiation treatment, can be prevented when acupuncture is part of a patient's treatment regimen.

23 Mar 2011

Researchers discover novel gene regulation mechanism that contributes to HCC development

Researchers at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine have discovered a novel mechanism in gene regulation that contributes to the development of a form of liver cancer called hepatocellular carcinoma.

23 Mar 2011

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced a positive outcome from a pivotal Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

21 Mar 2011

Carcinoma News and Research

Further Reading

Thalidomide provides new hope for patients with difficult to treat liver cancer

Biocept, academic collaborators' posters on CTCs to be presented at AACR meeting

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

DSP, Intercept enter license agreement for OCA

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Smoking withdrawal after liver transplantation may protect against neoplasia development

Smoking cessation after liver transplantation reduces incidence of malignancy

Nordion presents TheraSphere Phase II trial results against liver metastases at SIR meeting

AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting

Scientists receive CFCF-AACR grants for carcinoid, pancreatic neuroendocrine tumor research

VARI, Gentel Biosciences receive U.S. Patent for new glycan detection technology

MicroRNAs may play a key role in future medicine

FDA approves Nordion's TheraSphere IDE for Phase III trial to treat HCC

MD Anderson receives $2.7 million NCI grant for acupuncture study in cancer

Researchers discover novel gene regulation mechanism that contributes to HCC development

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News